{"created":"2023-05-15T14:55:44.050240+00:00","id":75677,"links":{},"metadata":{"_buckets":{"deposit":"725214d7-b619-4b27-837c-8e22da999225"},"_deposit":{"created_by":1,"id":"75677","owners":[1],"pid":{"revision_id":0,"type":"depid","value":"75677"},"status":"published"},"_oai":{"id":"oai:repo.qst.go.jp:00075677","sets":["1"]},"author_link":["908021","908024","908027","908018","908019","908022","908025","908026","908028","908020","908023"],"item_8_biblio_info_7":{"attribute_name":"書誌情報","attribute_value_mlt":[{"bibliographicIssueDates":{"bibliographicIssueDate":"2019-02","bibliographicIssueDateType":"Issued"},"bibliographicIssueNumber":"5","bibliographicPageEnd":"1664","bibliographicPageStart":"1653","bibliographicVolumeNumber":"110","bibliographic_titles":[{"bibliographic_title":"Cancer Science"}]}]},"item_8_description_5":{"attribute_name":"抄録","attribute_value_mlt":[{"subitem_description":"Podoplanin is a type I transmembrane sialomucin-like glycoprotein that is highly expressed in malignant mesothelioma. The rat-human chimeric antibody NZ-12 has high affinity for human podoplanin and antibody-dependent cellular cytotoxicity, and is applicable for radioimmunotherapy (RIT) to enhance the antitumor effect. In the present study, we evaluated the in vivo and in vitro properties of radiolabeled NZ-12 and the antitumor effect of RIT with  Y-labeled NZ-12 in an NCI-H226 (H226) malignant mesothelioma xenograft mouse model.  In-labeled NZ-12 bound specifically to H226 cells with high affinity, and accumulation was high in H226 tumors but low in major organs. RIT with  Y-labeled NZ-12 significantly suppressed tumor growth and prolonged survival without body weight loss and obvious adverse effects. Higher podoplanin expression levels were observed in human mesothelioma specimens, suggesting higher tumor accumulation of  Y-labeled NZ-12 in patients compared with the H226 tumor xenografts. Our findings suggest that  Y-labeled NZ-12 is a promising RIT agent as a new therapeutic option for malignant mesothelioma that warrants further clinical studies to evaluate the dosimetry and efficacy in patients. This article is protected by copyright. All rights reserved.","subitem_description_type":"Abstract"}]},"item_8_publisher_8":{"attribute_name":"出版者","attribute_value_mlt":[{"subitem_publisher":"日本癌学会"}]},"item_8_relation_13":{"attribute_name":"PubMed番号","attribute_value_mlt":[{"subitem_relation_type_id":{"subitem_relation_type_id_text":"30801908","subitem_relation_type_select":"PMID"}}]},"item_8_relation_14":{"attribute_name":"DOI","attribute_value_mlt":[{"subitem_relation_type_id":{"subitem_relation_type_id_text":"10.1111/cas.13979","subitem_relation_type_select":"DOI"}}]},"item_8_source_id_9":{"attribute_name":"ISSN","attribute_value_mlt":[{"subitem_source_identifier":"1349-7006","subitem_source_identifier_type":"ISSN"}]},"item_access_right":{"attribute_name":"アクセス権","attribute_value_mlt":[{"subitem_access_right":"metadata only access","subitem_access_right_uri":"http://purl.org/coar/access_right/c_14cb"}]},"item_creator":{"attribute_name":"著者","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{"creatorName":"Sudo, Hitomi"}],"nameIdentifiers":[{"nameIdentifier":"908018","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Tsuji, Atsushi"}],"nameIdentifiers":[{"nameIdentifier":"908019","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Sugyo, Aya"}],"nameIdentifiers":[{"nameIdentifier":"908020","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Saga, Tsuneo"}],"nameIdentifiers":[{"nameIdentifier":"908021","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"K Kaneko, Mika"}],"nameIdentifiers":[{"nameIdentifier":"908022","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Kato, Yukinari"}],"nameIdentifiers":[{"nameIdentifier":"908023","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Higashi, Tatsuya"}],"nameIdentifiers":[{"nameIdentifier":"908024","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Sudo, Hitomi","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"908025","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Tsuji, Atsushi","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"908026","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Sugyo, Aya","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"908027","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Higashi, Tatsuya","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"908028","nameIdentifierScheme":"WEKO"}]}]},"item_language":{"attribute_name":"言語","attribute_value_mlt":[{"subitem_language":"eng"}]},"item_resource_type":{"attribute_name":"資源タイプ","attribute_value_mlt":[{"resourcetype":"journal article","resourceuri":"http://purl.org/coar/resource_type/c_6501"}]},"item_title":"Therapeutic efficacy evaluation of radioimmunotherapy with Y-90-labeled anti-podoplanin antibody NZ-12 for mesothelioma","item_titles":{"attribute_name":"タイトル","attribute_value_mlt":[{"subitem_title":"Therapeutic efficacy evaluation of radioimmunotherapy with Y-90-labeled anti-podoplanin antibody NZ-12 for mesothelioma"}]},"item_type_id":"8","owner":"1","path":["1"],"pubdate":{"attribute_name":"公開日","attribute_value":"2019-03-01"},"publish_date":"2019-03-01","publish_status":"0","recid":"75677","relation_version_is_last":true,"title":["Therapeutic efficacy evaluation of radioimmunotherapy with Y-90-labeled anti-podoplanin antibody NZ-12 for mesothelioma"],"weko_creator_id":"1","weko_shared_id":-1},"updated":"2023-05-15T21:07:30.413730+00:00"}